Metabolic Syndrome and Its Treatment Affects Response to Androgen Deprivation Therapy in Metastatic Prostate Cancer
Adam S. Kibel, MD, and Jiun-Hung Geng, of the Brigham’s Division of Urology, and colleagues recently conducted the first study of how the combination of metabolic syndrome and its treatment affect response to androgen deprivation therapy in castration-sensitive prostate cancer.
Read More...